Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+

INTRODUCTION: Currently there is limited data to drive clinical decision making regarding  the choice of biologic/targeted synthetic disease-modifying antirheumatic drugs (DMARD); thus, head-to-head comparisons are needed to help guide prescribing. In recent years, significant advancements have help...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrold, Leslie R., Wittstock, Keith, Kelly, Sheila, Han, Xue, Shan, Ying, Guo, Lin, Moore, Page C., Khaychuk, Vadim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140197/
https://www.ncbi.nlm.nih.gov/pubmed/36749478
http://dx.doi.org/10.1007/s40744-022-00523-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140197/
https://www.ncbi.nlm.nih.gov/pubmed/36749478
http://dx.doi.org/10.1007/s40744-022-00523-z

Ejemplares similares